Dr. Adam Kibel on Treating Bone Metastases in Prostate Cancer

Video

Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer.

prostate cancer

Adam Kibel, MD, chief of urology, Dana Farber Cancer Institute, Brigham and Women's Hospital, discusses how to properly treatpatients with bone metastases and what the goals of the treatments are. 

Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer. The combination significantly improved overall survival (OS), which Kibel says is proof enough to implement docetaxel in patients with bone metastatic cancer.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Understanding Patient Distress via EHR in Community Oncology

Understanding Patient Distress via EHR in Community Oncology

Jordyn Sava
May 22nd 2025
Article

Kat M. Aguilar, MPH, discussed the findings of the recent study evaluating the early adoption of the distress thermometer.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Biomarker Testing Expands in Metastatic Bladder Cancer

Biomarker Testing Expands in Metastatic Bladder Cancer

Jordyn Sava
May 21st 2025
Article

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

FDA Oks Phase 3 Trial of PT-112 in mCRPC Following Successful EOP2 Meeting

FDA Oks Phase 3 Trial of PT-112 in mCRPC Following Successful EOP2 Meeting

Jordyn Sava
May 20th 2025
Article

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of phase 2 meeting.

Read More

AI Predicts Prostate Cancer Prognosis Fairly Across Races

AI Predicts Prostate Cancer Prognosis Fairly Across Races

Jordyn Sava
May 20th 2025
Article

Mack Roach III, MD, discussed a study on artificial intelligence’s generalizability for prostate cancer across racial groups.

Read More